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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S321transcripted into cDNA. The mmu-miR-381-3p mimic/inhibitor were
transfected into cells with lipofectamine 2000. The miR-381-3p in
mouse embryo and degraded cartilage was stained with insitu
hybridization method.
Results: The miR-381 expression was elevated in chondrogenic ATDC5.
The in situ hybridization assay identiﬁed the presence of miR-381 in
degraded cartilage of osteoarthritis patients and in enchondral bone
formating claws of mouse embryo.
The miR-381 obviously suppressed the collagen 2 expression and
enhanced mmp13 expression.
Conclusions: The miR-381 may participate in chondrogenesis and
cartilage degradation by alleviating collagen 2 expression and
enhancing mmp13 expression.Nutraceuticals/ Dietary Supplements and OA
559
SHELLS FROM ROSE-HIP (ROSA CANINA) DO NOT REDUCE SYMPTOM
SCORES OR IMPROVE ANTI-INFLAMMATORY PROPERTY IN PATIENTS
WITH OSTEOARTHRITIS – A DOUBLE-BLIND, PLACEBO-CONTROLLED,
RANDOMIZED STUDY
K. Winther. Frederiksberg and Bispebjerg Hosp., Univ. of Copenhagen,
Copenhagen NV, Denmark
Purpose: Placebo controlled studies on a standardised rose-hip powder,
Hyben-Vital, based on daily intake of 2.5 g seeds and 2.5 g shells,
indicate alleviation of symptoms from osteoarthritis. The same powder
also shows anti-inﬂammatory properties, by lowering C-reactive pro-
tein (CRP) and erythrocyte sedimentation rate. On the latest OARSI
meeting, data from a partly blinded, exploratory study, on rose-hip
powder, based exclusively on shells, was presented. The study, which
did not include placebo or measurements of inﬂammatory markers,
suggested that the shell powder (2.25 g daily) could have equal, orperhaps stronger effect, than the double dose of said shell powder (4.5 g
daily), or even the original Hyben-Vital powder (5 g daily) containing
50% shells and 50% seeds. An inverse dose-response curve, where less
powder gives higher response, was introduced in the study. The
inclusion of a placebo arm would have made the study even stronger.
The present study, therefore, aims to test whether this low-dose shell
powder shows any impact on symptoms of OA and/or reduction in CRP,
when tested against placebo treatment.
Methods: Ninety-four patients, a sub fraction from a study on the
occurrence of common cold during the winter season (ClinicalTrials.gov
Identiﬁer NCT 01459952), all diagnosed with OA according to the cri-
teria of the American College of Rheumatology, participated in the
present study. Forty-seven patients received 90% rosehip shells and 10%
rose hip seeds in total (2.20 gram daily) and the remaining forty-seven
patients received placebo of similar taste and colour. All patients were
followed for 6 months. Pain and stiffness was estimated on a numerical
scale from 0-10 (more symptom - higher score) and patient’s global
assessment of disease severity (PGAD)was estimated on a 100mm scale
(WOMAC). Quality of life was estimated using SF-12, and CRP by normal
laboratory routine. The Wilcoxon tested within groups and the Man-
Whitney was used when comparing groups. A p-value less than 0.050
was regarded as statistically signiﬁcant. All data given is on the inten-
tion to treat basis. To further test if an impact from active treatment, if
present, was based on treatment it self or was possibly random - a dose
dependency tests - wasmade on both groups by testing for a correlation
between patient weight and symptom score.
Results: Pain declined as a result of active treatment from 4.72 þ/- 2.41
to 3.44 þ/- 2.19 (p<0.050). Placebo resulted in similar results: 4.91 þ/-
3.07 declined to 3.99 þ/-2.74, p<0.086. Man-Whitney p value <0.880.
Stiffness likewise declined in both groups. Active treatment: 3.57 þ/-
2.38 declined to 2.95 þ/- 1.88 (p<0.236) and placebo: 4.50 þ/- 2.93
declined to 3.80 þ/- 2.85, (p<0.033). Man-Whitney p value: 0.274. No
signiﬁcant change was observed in PGAD: active treatment 31.0 þ/-21
changing to 33.0 þ/-20.0 (p<0.527) and placebo 42.0 þ/-27 unchanged
42.0 þ/-24.0 (p<0.541). Mann-Whitney p-value 0.520. Quality of life
(SF-12 physical and SF-12 psychological) did not show any changes
(data not given). CRP remained unchanged during both treatments,
Mann-Whitney p-value: 0.347. There was no correlation between
patient weight and the change in symptom scores in either of the two
groups at any time point of the study (data not given). This demon-
strates a lack of effect of shell powder treatment. The lighter patient at
60 kg had the same lack of effect as had the heavier patient at 110 kg.
Conclusions: In regards to impact on symptom scores of OA, quality of
life and reduction in CRP, low-dose rose-hip powder based mainly on
shells, is comparable to placebo. The effect in symptom scores of OA,
quality of life and reduction in CRP seen in previous studies on stand-
ardised rose-hip powder from Rosa canina may be highly dependent on
the higher content of seeds.
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LOW-DOSE SEED AND SHELL POWDER FROM ROSE-HIP (ROSA
CANINA) CAN ALEVIATE SYMPTOMS OF OSTEOARTHRITIS AND
REDUCE C-REACTIVE PROTEIN IN PATIENTS SUFFERING FROM
OSTEOARTHRITIS
K. Winther. Frederiksberg and Bispebjerg Hosp., Univ. of Copenhagen,
Copenhagen NV, Denmark
Purpose: A meta-analysis has shown that a standardised rose-hip
powder, Hyben-Vital containing seeds and shells from Rosa canina,
reduces symptoms of osteoarthritis (OA), when used in the dose of 5 g
daily. The same remedy can also reduce markers of inﬂammation. The
aim of the present study was to test if the aforementioned rose-hip
powder, when given as a booster of 5 grams daily for 3 weeks, then
followed by 2.5 g for the following 9 weeks, would alleviate symptoms
of osteoarthritis and reduce C-reactive protein (CRP) in patients suf-
fering from OA of the hip or knee.
Methods: The study (ClinicalTrials.gov Identiﬁer NCT01459939) inclu-
ded 120 patients who were allocated randomly to either active treat-
ment: 5 grams daily for the ﬁrst 3 weeks followed by 2.5 gram daily for
the following 9 weeks, or placebo in a similar dose and of similar colour,
taste and smell. All the patients were diagnosed with OA according to
the criteria of the American College of Rheumatology. The WOMAC
questionnaire was used throughout. The primary effect variables were
pain and activity of daily living (ADL). A Secondary effect variable was
stiffness. CRP was estimated using normal laboratory routine. The
